Protocol for systematic review and meta-analysis for randomized clinical trials on patiromer efficacy and safety in subjects with heart failure
Main Article Content
Keywords
efficacy, heart failure, hyperkalemia, meta-analysis, patiromer, randomized controlled trials (RCTs), safety, sodium zirconium cyclosilicate, systematic review
Abstract
Background: We shall assess the efficacy and safety of patiromer in subjects with heart failure (HF) in randomized controlled trials (RCTs). Methods: The protocol has been developed supported the PRISMA-P checklist by using (PICO [population, intervention, comparators, and outcome]) items, for adult subjects with HF who have received patiromer in RCTs versus SZC or placebo to attain specific endpoint of control of hyperkalemia. The subjects with HF (population) receiving patiromer (intervention) are compared to placebo or other potassium binders (comparators), like sodium zirconium cyclosilicate (ZS-9, SZC, Lokelma®) for the non-inferiority or superiority in terms of effects on hyperkalemia (outcome) and alter in potassium serum levels. Results: Patiromer may provide an efficient treatment for hyperkalemia in subjects with HF receiving angiotensin-converting enzyme inhibitor (ACEi), angiotensin receptor blocker (ARB) and/or mineralocorticoids/aldosterone antagonists (MRA/AA). Patiromer may facilitate the clinical utility of RAAS inhibitors without discontinuation or interruption of therapy in subjects with HF. Patiromer may enable dose titration of AA without the danger of hyperkalemia. Patiromer is anticipated to halt recurrence of hyperkalemia in subjects with HF. Conclusion: Patiromer may provide safe and effective therapy for prevention, maintenance, management, and prevent recurrence of hyperkalemia in subjects with HF as compared to the other comparators.
References
2. Kumar R, Kanev L, Woods SD, et al. Managing hyperkalemia in high-risk patients in long-term care. Am J Manag Care. 2017;23(2 Suppl):S27-36.
3. Long B, Warix JR, Koyfman A. Controversies in management of hyperkalemia. J Emerg Med. 2018;55(2):192-205. https://doi. org/10.1016/j.jemer med.2018.04.004
4. Nunez J, Bayes-Genis A, Zannad F, et al. Long-term potassium monitoring and dynamics in heart failure and risk of mortality. Circulation. 2018;137(13):1320-30. https://doi.org/10.1161/circulationaha.117.030576
5. Collins AJ, Pitt B, Reaven N, et al. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes. Am J Nephrol. 2017;46(3):213-21. https://doi.org/10.1159/000479802
6. Kovesdy CP. Management of hyperkalaemia in chronic kidney disease. Nat Rev Nephrol. 2014;10(11):653-62. https://doi. org/10.1038/nrneph.2014.168
7. Seliger SL. Hyperkalemia in patients with chronic renal failure. Nephrol Dial Transplant. 2019 Dec 1;34(Suppl 3):iii12-8. https:// doi.org/10.1093/ndt/gfz231
8. Einhorn LM, Zhan M, Hsu VD, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med. 2009 Jun 22;169(12):1156-62. https://doi.org/10.1001/archinternmed.2009.132
9. Georgianos PI, Agarwal R. Revisiting RAAS blockade in CKD with newer potassium-binding drugs. Kidney Int. 2018;93(2):325- 34. https://doi.org/10.1016/j.kint.2017.08.038
10. Tzamaloukas AH, Glew RH. Efficacy and safety of patiromer in prevention and treatment of hyperkalemia. J Sympt Signs. 2013;2(6):475-484.
11. Veltassa® (patiromer) for oral suspension [package insert]. Redwood City, CA: Relypsa, Inc. 2018. https://www.veltassa.com/ pi.pdf
12. European Medicines Agency. Veltassa (patiromer). https://www.ema.europa.eu/en/medicines/human/EPAR/veltassa. Updated 19 June 2019. Accessed 30 April 2022
13. Sterns RH, Rojas M, Bernstein P, et al. Ion‐exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol. 2010;21:733-5. https://doi.org/10.1681/asn.2010010079
14. Agarwal R, Rossignol P, Garza D, et al. Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study. Am J Nephrol. 2018;48(3):172-180. https://doi.org/10.1159/000492622
15. Rajiv Agarwal, Patrick Rossignol, Jeffrey Budden, et al. Patiromer and Spironolactone in Resistant Hypertension and Advanced CKD: Analysis of the Randomized AMBER Trial. White Kidney360. 2021;2 (3):425-34; https://doi.org/10.34067/KID.0006782020
16. Shamseer L, Moher D, Clarke M, et al. PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349(jan02 1):g7647.
17. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1. https://doi.org/10.1186/2046-4053-4-1
18. Jadad AR, Moore RA, Carroll D,et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1-12. https://doi.org/10.1016/0197-2456(95)00134-4
19. Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64(4):401-6. https://doi.org/10.1016/j.jclinepi.2010.07.015
20. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383-94. https://doi.org/10.1016/j.jclinepi.2010.04.026
21. Morgan RL, Thayer KA, Bero L, et al. GRADE: Assessing the quality of evidence in environmental and occupational health. Environ Int. 2016;92-93:611-616. https://doi.org/10.1016/j.envint.2016.01.004
22. Pitt B, Anker SD, Bushinsky DA,et al . PEARL-HF Investigators. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011;32:820-8. https://doi.org/10.1093/eurheartj/ehq502
23. Pitt B, Bakris GL, Bushinsky DA, et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail. 2015;17(10):1057-5. https://doi. org/10.1002/ejhf.402
24. Weir MR, Bakris GL, Bushinsky DA, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015;372(3):211-21. https://doi.org/10.1056/NEJMoa1410853
25. Pitt B, Bushinsky DA, Kitzman DW, et al. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. ESC Heart Fail. 2018;5(3):257-66. https://doi. org/10.1002/ehf2.12265
26. Bolaños JA, Seliger SL. Recurrent Hyperkalemia in Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Treatment: Stuck between a Rock and a Hard Place. Clin J Am Soc Nephrol. 2021;16(3):345-7. https://doi.org/10.2215/CJN.00950121
27. Bakris GL, Pitt B, Weir MR, et al. AMETHYST-DA Investigators. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA. 2015;314:151-161. https://doi. org/10.1001/ jama.2015.7446
28. Meaney CJ, Beccari MV, Yang Y, et al. Systematic review and meta‐analysis of patiromer and sodium zirconium cyclosilicate: a new armamentarium for the treatment of hyperkalemia. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2017;37(4):401-1. https://doi.org/10.1002/phar.1906. 10.1002/phar.1906
29. Natale P, Palmer SC, Ruospo M, et al. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease. Cochrane Database Syst Rev. 2020;6(6):CD013165. https://doi.org/10.1002/14651858.CD013165.pub2
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.